NCT02229734View on ClinicalTrials.gov

Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer - Protocol 2

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

August 31, 2017

Study Completion Date

June 1, 2021

Conditions
Prostate Cancer
Interventions
RADIATION

Radiation

Radiation: Radiotherapy 7 gray (Gy) per week over 5 weeks (35Gy)

DRUG

Androgen Suppression

Leuprolide 45mg every 6 months for a total of 18 months

Trial Locations (1)

N6A 4L6

London Regional Cancer Program of the Lawson Health Research Institute, London

All Listed Sponsors
lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

NCT02229734 - Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer - Protocol 2 | Biotech Hunter | Biotech Hunter